ESTRELLA IMMUNOPHARMA, INC. Increase (Decrease) in Accounts Payable and Accrued Liabilities
ESTRELLA IMMUNOPHARMA, INC. (ESLA) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of $108.66 thousand for the 6-month period ending 2023-06-30, per its 10-Q filed 2023-08-01.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2023-08-01
- ESTRELLA IMMUNOPHARMA, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2023-06-30 was $62.82K, a 37.46% decline year-over-year.
- ESTRELLA IMMUNOPHARMA, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2023-03-31 was $45.84K, a 1427.83% increase year-over-year.
- ESTRELLA IMMUNOPHARMA, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2022-12-31 was $122.67K.
- ESTRELLA IMMUNOPHARMA, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2022-09-30 was $100.05K.
- ESTRELLA IMMUNOPHARMA, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2022 was $326.17K.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2023-06-30 | $62.82K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-01 | $108.66K 10-Q · filed 2023-08-01 | $231.33K derived: sum of 3 quarters · filed 2023-08-01 | $331.38K derived: sum of 4 quarters · filed 2023-08-01 |
| 2023-03-31 | $45.84K 10-Q · filed 2023-05-18 | $168.50K derived: sum of 2 quarters · filed 2023-05-18 | $268.55K derived: sum of 3 quarters · filed 2023-05-18 | $369.00K derived: sum of 4 quarters · filed 2023-08-01 |
| 2022-12-31 | $122.67K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | $222.72K derived: sum of 2 quarters · filed 2023-03-14 | $323.17K derived: sum of 3 quarters · filed 2023-08-01 | $326.17K 10-K · filed 2023-03-14 |
| 2022-09-30 | $100.05K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $200.50K derived: sum of 2 quarters · filed 2023-08-01 | $203.50K 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $100.45K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-01 | $103.45K 10-Q · filed 2023-08-01 | ||
| 2022-03-31 | $3.00K 10-Q · filed 2023-05-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |